Pentraxins and Alzheimer's disease: At the interface between biomarkers and pharmacological targets

Ageing Research Reviews

Volumn 11, Issue 2, 2012, Pages 189-198

  Osera, Cecilia ^a   Pascale, Alessia ^a   Amadio, Marialaura ^a   Venturini, Letizia ^a,b   Govoni, Stefano ^a   Ricevuti, Giovanni ^a,b  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Alzheimer's disease; Microglia; Neurodegeneration; Neuroinflammation; Pentraxins

Indexed keywords

C REACTIVE PROTEIN; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; NEURONAL PENTRAXIN; NONSTEROID ANTIINFLAMMATORY AGENT; PENTRAXIN; PENTRAXIN 3; PLASMA PROTEIN; SERUM AMYLOID P; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; CEREBROSPINAL FLUID; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE COURSE; HUMAN; INNATE IMMUNITY; LIVER CELL; MACROPHAGE; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NEUTROPHIL; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN BINDING; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; UPREGULATION;

ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; BRAIN; C-REACTIVE PROTEIN; HUMANS; INFLAMMATION MEDIATORS; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; SERUM AMYLOID A PROTEIN; SERUM AMYLOID P-COMPONENT;

EID: 84855186126     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2011.12.004     Document Type: Review

References (114)

1. Abad M.A., Enguita M., DeGregorio-Rocasolano N., Ferrer I., Trullas R. Neuronal pentraxin 1 contributes to the neuronal damage evoked by amyloid-beta and is overexpressed in dystrophic neurites in Alzheimer's brain. J. Neurosci. 2006, 26:12735-12747.
2. Agrawal A., Singh P.P., Bottazzi B., Garlanda C., Mantovani A. Pattern recognition by pentraxins. Adv. Exp. Med. Biol. 2009, 653:98-116.
3. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21:383-421.
4. Alvarez X.A., Franco A., Fernández-Novoa L., Cacabelos R. Blood levels of histamine, IL-1 beta, and TNF-alpha in patients with mild to moderate Alzheimer disease. Mol. Chem. Neuropathol. 1996, 29:237-252.
5. Benzing W.C., Wujek J.R., Ward E.K., Shaffer D., Ashe K.H., Younkin S.G., Brunden K.R. Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol. Aging 1999, 20:581-589.
6. Bjartmar L., Huberman A.D., Ullian E.M., Rentería R.C., Liu X., Xu W., Prezioso J., Susman M.W., Stellwagen D., Stokes C.C., Cho R., Worley P., Malenka R.C., Ball S., Peachey N.S., Copenhagen D., Chapman B., Nakamoto M., Barres B.A., Perin M.S. Neuronal pentraxins mediate synaptic refinement in the developing visual system. J. Neurosci. 2006, 26:6269-6281.
7. Blasko I., Marx F., Steiner E., Hartmann T., Grubeck-Loebenstein B. TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J. 1999, 13:63-68.
8. Blasko I., Stampfer-Kountchev M., Robatscher P., Veerhuis R., Eikelenboom P., Grubeck-Loebenstein B. How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell 2004, 3:169-176.
9. Bodin K., Ellmerich S., Kahan M.C., Tennent G.A., Loesch A., Gilbertson J.A., Hutchinson W.L., Mangione P.P., Gallimore J.R., Millar D.J., Minogue S., Dhillon A.P., Taylor G.W., Bradwell A.R., Petrie A., Gillmore J.D., Bellotti V., Botto M., Hawkins P.N., Pepys M.B. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010, 468:93-97.
10. Bottazzi B., Doni A., Garlanda C., Mantovani A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu. Rev. Immunol. 2010, 28:157-183.
11. Botto M., Hawkins P.N., Bickerstaff M.C., Herbert J., Bygrave A.E., McBride A., Hutchinson W.L., Tennent G.A., Walport M.J., Pepys M.B. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat. Med. 1997, 3:855-859.
12. Brazil M.I., Chung H., Maxfield F.R. Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer's disease amyloid fibrils by microglia. J. Biol. Chem. 2000, 275:16941-16947.
13. Brügger-Andersen T., Pönitz V., Kontny F., Staines H., Grundt H., Sagara M., Nilsen D.W. The long pentraxin 3 (PTX3): a novel prognostic inflammatory marker for mortality in acute chest pain. Thromb. Haemost. 2009, 102:555-563.
14. Buée L., Bussière T., Buée-Scherrer V., Delacourte A., Hof P.R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 2000, 33:95-130.
15. Cunningham C., Wilcockson D.C., Campion S., Lunnon K., Perry V.H. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J. Neurosci. 2005, 25:9275-9284.
16. Deban L., Jaillon S., Garlanda C., Bottazzi B., Mantovani A. Pentraxins in innate immunity: lessons from PTX3. Cell Tissue Res. 2011, 343:237-249.
17. DeGregorio-Rocasolano N., Gasull T., Trullas R. Overexpression of neuronal pentraxin 1 is involved in neuronal death evoked by low K(+) in cerebellar granule cells. J. Biol. Chem. 2001, 276:796-803.
18. Dodds D.C., Omeis I.A., Cushman S.J., Helms J.A., Perin M.S. Neuronal pentraxin receptor, a novel putative integral membrane pentraxin that interacts with neuronal pentraxin 1 and 2 and taipoxin-associated calcium-binding protein 49. J. Biol. Chem. 1997, 272:21488-21494.
19. DuClos T.W., Mold C., Stump R.F. Identification of a polypeptide sequence that mediates nuclear localization of the acute phase protein C-reactive protein. J. Immunol. 1990, 145:3869-3875.
20. Duffield., Lupher J.S., M.L.Jr. PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis. Drug News Perspect. 2010, 23:305-315.
21. Duong T., Acton P.J., Johnson R.A. The in vitro neuronal toxicity of pentraxins associated with Alzheimer's disease brain lesions. Brain Res. 1998, 813:303-312.
22. Duong T., Nikolaeva M., Acton P.J. C-reactive protein-like immunoreactivity in the neurofibrillary tangles of Alzheimer's disease. Brain Res. 1997, 749:152-156.
23. Duong T., Pommier E.C., Scheibel A.B. Immunodetection of the amyloid P component in Alzheimer's disease. Acta Neuropathol. 1989, 78:429-437.
24. Edison P., Archer H.A., Gerhard A., Hinz R., Pavese N., Turkheimer F.E., Hammers A., Tai Y.F., Fox N., Kennedy A., Rossor M., Brooks D.J. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol. Dis. 2008, 32:412-419.
25. Engelhart M.J., Geerlings M.I., Meijer J., Kiliaan A., Ruitenberg A., van Swieten J.C., Stijnen T., Hofman A., Witteman J.C., Breteler M.M. Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. Arch. Neurol. 2004, 61:668-672.
26. Familian A., Eikelenboom P., Veerhuis R. Minocycline does not affect amyloid beta phagocytosis by human microglial cells. Neurosci. Lett. 2007, 416:87-91.
27. Fiala M., Veerhuis R. Biomarkers of inflammation and amyloid-beta phagocytosis in patients at risk of Alzheimer disease. Exp. Gerontol. 2010, 45:57-63.
28. Forlenza O.V., Diniz B.S., Talib L.L., Mendonça V.A., Ojopi E.B., Gattaz W.F., Teixeira A.L. Increased serum IL-1beta level in Alzheimer's disease and mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 2009, 28:507-512.
29. Garlanda C., Bottazzi B., Bastone A., Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu. Rev. Immunol. 2005, 23:337-366.
30. Garlanda C., Hirsch E., Bozza S., Salustri A., De Acetis M., Nota R., Maccagno A., Riva F., Bottazzi B., Peri G., Doni A., Vago L., Botto M., De Santis R., Carminati P., Siracusa G., Altruda F., Vecchi A., Romani L., Mantovani A. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 2002, 420:182-186.
31. Garlanda C., Maina V., Cotena A., Moalli F. The soluble pattern recognition receptor pentraxin-3 in innate immunity, inflammation and fertility. J. Reprod. Immunol. 2009, 83:128-133.
32. Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934.
33. Gómez-Tortosa E., Gonzalo I., Fanjul S., Sainz M.J., Cantarero S., Cemillán C., Yébenes J.G., del Ser T. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Arch. Neurol. 2003, 60:1218-1222.
34. Griffin W.S., Sheng J.G., Roberts G.W., Mrak R.E. IL-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J. Neuropathol. Exp. Neurol. 1995, 54:276-281.
35. Griffin W.S., Sheng J.G., Royston M.C., Gentleman S.M., McKenzie J.E., Graham D.I., Roberts G.W., Mrak R.E. Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol. 1998, 8:65-72.
36. Gupta A., Watkins A., Thomas P., Majer R., Habubi N., Morris G., Pansari K. Coagulation and inflammatory markers in Alzheimer's and vascular dementia. Int. J. Clin. Pract. 2004, 59:52-57.
37. Hamazaki H. Amyloid P component promotes aggregation of Alzheimer's beta-amyloid peptide. Biochem. Biophys. Res. Commun. 1995, 211:349-353.
38. Hampel H., Schoen D., Schwarz M.J., Kötter H.U., Schneider C., Sunderland T., Dukoff R., Levy J., Padberg F., Stübner S., Buch K., Müller N., Möller H.J. Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease. Neurosci. Lett. 1997, 13:143-146.
39. Harikumar K.B., Aggarwal B.B. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 2008, 7:1020-1035.
40. Hawkins P.N., Rossor M.N., Gallimore J.R., Miller B., Moore E.G., Pepys M.B. Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease. Biochem. Biophys. Res. Commun. 1994, 201:722-726.
41. 123I-labeled serum amyloid P component in systemic amyloidosis. J. Nucl. Med. 2007, 48:865-872.
42. Holmes C., Cunningham C., Zotova E., Woolford J., Dean C., Kerr S., Culliford D., Perry V.H. Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009, 73:768-774.
43. Huell M., Strauss S., Volk B., Berger M., Bauer J. Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients. Acta Neuropathol. 1995, 89:544-551.
44. Iwamoto N., Nishiyama E., Ohwada J., Arai H. Demonstration of CRP immunoreactivity in brains of Alzheimer's disease: immunohistochemical study using formic acid pretreatment of tissue sections. Neurosci. Lett. 1994, 177:23-26.
45. Jeon H., Lee S., Lee W.H., Suk K. Analysis of glial secretome: the long pentraxin PTX3 modulates phagocytic activity of microglia. J. Neuroimmunol. 2010, 229:63-72.
46. Kalaria R.N., Grahovac I. Serum amyloid P immunoreactivity in hippocampal tangles, plaques and vessels: implications for leakage across the blood-brain barrier in Alzheimer's disease. Brain Res. 1990, 516:349-353.
47. Kirkpatrick L.L., Matzuk M.M., Dodds D.C., Perin M.S. Biochemical interactions of the neuronal pentraxins. Neuronal pentraxin (NP) receptor binds to taipoxin and taipoxin-associated calcium-binding protein 49 via NP1 and NP2. J. Biol. Chem. 2000, 275:17786-17792.
48. Ko C.Y., Chang L.H., Lee Y.C., Sterneck E., Cheng C.P., Chen S.H., Huang A.M., Tseng J.T., Wang J.M. CCAAT/enhancer binding protein delta (CEBPD) elevating PTX3 expression inhibits macrophage-mediated phagocytosis of dying neuron cells. Neurobiol. Aging 2010, (published online Nov. 26). 10.1016/j.neurobiolaging.2010.09.017.
49. Koch S.M., Ullian E.M. Neuronal pentraxins mediate silent synapse conversion in the developing visual system. J. Neurosci. 2010, 30:5404-5414.
50. Koenigsknecht-Talboo J., Landreth G.E. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J. Neurosci. 2005, 25:8240-8249.
51. Kolstoe S.E., Ridha B.H., Bellotti V., Wang N., Robinson C.V., Crutch S.J., Keir G., Kukkastenvehmas R., Gallimore J.R., Hutchinson W.L., Hawkins P.N., Wood S.P., Rossor M.N., Pepys M.B. Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:7619-7623.
52. Kopec K.K., Carroll R.T. Alzheimer's beta-amyloid peptide 1-42 induces a phagocytic response in murine microglia. J. Neurochem. 1998, 71:2123-2131.
53. Latini R., Maggioni A.P., Peri G., Gonzini L., Lucci D., Mocarelli P., Vago L., Pasqualini F., Signorini S., Soldateschi D., Tarli L., Schweiger C., Fresco C., Cecere R., Tognoni G., Mantovani A. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004, 110:2349-2354.
54. Lee Y.J., Han S.B., Nam S.Y., Oh K.W., Hong J.T. Inflammation and Alzheimer's disease. Arch. Pharm. Res. 2010, 33:1539-1556.
55. Libby P., Ridker P.M. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am. J. Med. 2004, 116(Suppl. 6A):9S-16S.
56. Locascio J.J., Fukumoto H., Yap L., Bottiglieri T., Growdon J.H., Hyman B.T., Irizarry M.C. Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch. Neurol. 2008, 65:776-785.
57. 123I-serum amyloid P component in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1998, 12:208-210.
58. Macy E.M., Hayes T.E., Tracy R.P. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin. Chem. 1997, 43:52-58.
59. Mancinella A., Mancinella M., Carpinteri G., Bellomo A., Fossati C., Gianturco V., Iori A., Ettorre E., Troisi G., Marigliano V. Is there a relationship between high C-reactive protein (CRP) levels and dementia?. Arch. Gerontol. Geriatr. 2009, 49(Suppl. 1):185-194.
60. Margheri F., Serratì S., Lapucci A., Chillà A., Bazzichi L., Bombardieri S., Kahaleh B., Calorini L., Bianchini F., Fibbi G., Del Rosso M. Modulation of the angiogenic phenotype of normal and systemic sclerosis endothelial cells by gain-loss of function of pentraxin 3 and matrix metalloproteinase 12. Arthritis Rheum. 2010, 62:2488-2498.
61. McGeer E.G., McGeer P.L. Inflammatory processes in Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:741-749.
62. McGeer E.G., Yasojima K., Schwab C., McGeer P.L. The pentraxins: possible role in Alzheimer's disease and other innate inflammatory diseases. Neurobiol. Aging 2001, 22:843-848.
63. Mehlhorn G., Hollborn M., Schliebs R. Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int. J. Dev. Neurosci. 2000, 18:423-431.
64. Mulder C., Schoonenboom S.N., Wahlund L.O., Scheltens P., van Kamp G.J., Veerhuis R., Hack C.E., Blomberg M., Schutgens R.B., Eikelenboom P. CSF markers related to pathogenetic mechanisms in Alzheimer's disease. J. Neural Transm. 2002, 109:1491-1498.
65. Mulder S.D., van der Hack C.E., Flier W.M., Schelten P., Blankenstein M.A., Veerhuis R. Evaluation of intrathecal serum amyloid P (SAP) and C-reactive protein (CRP) synthesis in Alzheimer's disease with the use of index values. J. Alzheimers Dis. 2010, 22:1073-1079.
66. Muller B., Peri G., Doni A., Torri V., Landmann R., Bottazzi B., Mantovani A. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit. Care Med. 2001, 29:1404-1407.
67. Nauta A.J., Bottazzi B., Mantovani A., Salvatori G., Kishore U., Schwaeble W.J., Gingras A.R., Tzima S., Vivanco F., Egido J., Tijsma O., Hack E.C., Daha M.R., Roos A. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur. J. Immunol. 2003, 33:465-473.
68. O'Bryant S.E., Waring S.C., Hobson V., Hall J.R., Moore C.B., Bottiglieri T., Massman P., Diaz-Arrastia R. Decreased C-reactive protein levels in Alzheimer disease. J. Geriatr. Psychiatry Neurol. 2010, 23:49-53.
69. Paganelli R., Di Iorio A., Patricelli L., Ripani F., Sparvieri E., Faricelli R., Iarlori C., Porreca E., Di Gioacchino M., Abate G. Proinflammatory cytokines in sera of elderly patients with dementia: levels in vascular injury are higher than those of mild-moderate Alzheimer's disease patients. Exp. Gerontol. 2002, 37:257-263.
70. Pepys M.B., Herbert J., Hutchinson W.L., Tennent G.A., Lachmann H.J., Gallimore J.R., Lovat L.B., Bartfai T., Alanine A., Hertel C., Hoffmann T., Jakob-Roetne R., Norcross R.D., Kemp J.A., Yamamura K., Suzuki M., Taylor G.W., Murray S., Thompson D., Purvis A., Kolstoe S., Wood S.P., Hawkins P.N. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002, 417:254-259.
71. Ravaglia G., Forti P., Maioli F., Chiappelli M., Montesi F., Tumini E., Mariani E., Licastro F., Patterson C. Blood inflammatory markers and risk of dementia: the Conselice study of brain aging. Neurobiol. Aging 2007, 28:1810-1820.
72. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
73. Rogers J., Lue L.F. Microglial chemotaxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer's disease. Neurochem. Int. 2001, 39:333-340.
74. Rostagno A., Lashley T., Ng D., Meyerson J., Braendgaard H., Plant G., Bojsen-Moller M., Holton J., Frangione B., Revesz T., Ghiso J. Preferential association of serum amyloid P component with fibrillar deposits in familial British and Danish dementias: similarities with Alzheimer's disease. J. Neurol. Sci. 2007, 257:88-96.
75. Rusnati M., Camozzi M., Moroni E., Bottazzi B., Peri G., Indraccolo S., Amadori A., Mantovani A., Presta M. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood 2004, 104:92-99.
76. Salio M., Chimenti S., De Angelis N., Molla F., Maina V., Nebuloni M., Pasqualini F., Latini R., Garlanda C., Mantovani A. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2008, 117:1055-1064.
77. Salminen A., Ojala J., Kauppinen A., Kaarniranta K., Suuronen T. Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog. Neurobiol. 2009, 87:181-194.
78. Salustri A., Garlanda C., Hirsch E., De Acetis M., Maccagno A., Bottazzi B., Doni A., Bastone A., Mantovani G., Beck Peccoz P., Salvatori G., Mahoney D.J., Day A.J., Siracusa G., Romani L., Mantovani A. PTX3 plays a key role in the organization of the cumulus oophorus extracellular matrix and in in vivo fertilization. Development 2004, 131:1577-1586.
79. Schmidt R., Schmidt H., Curb J.D., Masaki K., White L.R., Launer L.J. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia aging study. Ann. Neurol. 2002, 52:168-174.
80. Schuitemaker A., Dik M.G., Veerhuis R., Scheltens P., Schoonenboom N.S., Hack C.E., Blankenstein M.A., Jonker C. Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol. Aging 2009, 30:1885-1889.
81. Schwab C., McGeer P.L. Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders. J. Alzheimers Dis. 2008, 13:359-369.
82. Schwab C., Steele J.C., McGeer E.G., McGeer P.L. Amyloid P immunoreactivity precedes C4d deposition on extracellular neurofibrillary tangles. Acta Neuropathol. 1997, 93:87-92.
83. Shah K., Qureshi S.U., Johnson M., Parikh N., Schulz P.E., Kunik M.E. Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am. J. Geriatr. Pharmacother. 2009, 7:250-261.
84. Shephard E.G., Smith P.J., Coetzee S., Strachan A.F., de Beer F.C. Pentraxin binding to isolated rat liver nuclei. Biochem. J. 1991, 279:257-262.
85. Shi J., Perry G., Berridge M.S., Aliev G., Siedlak S.L., Smith M.A., LaManna J.C., Friedland R.P. Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. J. Nucl. Med. 2002, 43:1044-1051.
86. Shibata N., Ohnuma T., Takahashi T., Baba H., Ishizuka T., Ohtsuka M., Ueki A., Nagao M., Arai H. Effect of IL-6 polymorphism on risk of Alzheimer disease: genotype-phenotype association study in Japanese cases. Am. J. Med. Genet. 2002, 114:436-439.
87. Souza D.G., Amaral F.A., Fagundes C.T., Coelho F.M., Arantes R.M., Sousa L.P., Matzuk M.M., Garlanda C., Mantovani A., Dias A.A., Teixeira M.M. The long pentraxin PTX3 is crucial for tissue inflammation after intestinal ischemia and reperfusion in mice. Am. J. Pathol. 2009, 174:1309-1318.
88. Steel D.M., Whitehead A.S. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol. Today 1994, 15:81-88.
89. Streit W.J. Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 2002, 40:133-139.
90. Szalai A.J. The antimicrobial activity of C-reactive protein. Microbes Infect. 2002, 4:201-205.
91. Szekely C.A., Zandi P.P. Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence. CNS Neurol. Disord. Drug Targets 2010, 9:132-139.
92. Tarkowski E., Blennow K., Wallin A., Tarkowski A. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J. Clin. Immunol. 1999, 19:223-230.
93. Tennent G.A., Lovat L.B., Pepys M.B. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:4299-4303.
94. Teunissen C.E., van Boxtel M.P., Bosma H., Bosmans E., Delanghe J., De Bruijn C., Wauters A., Maes M., Jolles J., Steinbusch H.W., de Vente J. Inflammation markers in relation to cognition in a healthy aging population. J. Neuroimmunol. 2003, 134:142-150.
95. Tuppo E.E., Arias H.R. The role of inflammation in Alzheimer's disease. Int. J. Biochem. Cell Biol. 2005, 37:289-305.
96. Vallieres L., Rivest S. Regulation of the genes encoding IL-6, its receptor, and gp130 in the rat brain in response to the immune activator lipopolysaccharide and the proinflammatory cytokine IL-1beta. J. Neurochem. 1997, 69:1668-1683.
97. van Oijen M., Witteman J.C., Hofman A., Koudstaal P.J., Breteler M.M. Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke 2005, 36:2637-2641.
98. Varani S., Elvin J.A., Yan C., DeMayo J., DeMayo F.J., Horton H.F., Byrne M.C., Matzuk M.M. Knockout of pentraxin 3, a downstream target of growth differentiation factor-9, causes female subfertility. Mol. Endocrinol. 2002, 16:1154-1167.
99. Veerhuis R. Histological and direct evidence for the role of complement in the neuroinflammation of AD. Curr. Alzheimer Res. 2011, 8:34-58.
100. Veerhuis R., Van Breemen M.J., Hoozemans J.M., Morbin M., Ouladhadj J., Tagliavini F., Eikelenboom P. Amyloid beta plaque-associated proteins C1q and SAP enhance the Abeta1-42 peptide-induced cytokine secretion by adult human microglia in vitro. Acta Neuropathol. 2003, 105:135-144.
101. Verma S., Szmitko P.E., Ridker P.M. C-reactive protein comes of age. Nat. Clin. Pract. Cardiovasc. Med. 2005, 2:29-36.
102. Verschuren L., Wielinga P.Y., van Duyvenvoorde W., Tijani S., Toet K., van Ommen B., Kooistra T., Kleemann R. A dietary mixture containing fish oil, resveratrol, lycopene, catechins, and vitamins E and C reduces atherosclerosis in transgenic mice. J. Nutr. 2011, 141:863-869.
103. Verwey N.A., Schuitemaker A., van der Flier W.M., Mulder S.D., Mulder C., Hack C.E., Scheltens P., Blankenstein M.A., Veerhuis R. Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2008, 26:522-527.
104. Walter S., Letiembre M., Liu Y., Heine H., Penke B., Hao W., Bode B., Manietta N., Walter J., Schulz-Schuffer W., Fassbender K. Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cell. Physiol. Biochem. 2007, 20:947-956.
105. Webster S.D., Yang A.J., Margol L., Garzon-Rodriguez W., Glabe C.G., Tenner A.J. Complement component C1q modulates the phagocytosis of Abeta by microglia. Exp. Neurol. 2000, 161:127-138.
106. Xu G., Zhou Z., Zhu W., Fan X., Liu X. Plasma C-reactive protein is related to cognitive deterioration and dementia in patients with mild cognitive impairment. J. Neurol. Sci. 2009, 284:77-80.
107. Yaffe K., Lindquist K., Penninx B.W., Simonsick E.M., Pahor M., Kritchevsky S., Launer L., Kuller L., Rubin S., Harris T. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003, 61:76-80.
108. Yano Y., Matsuda S., Hatakeyama K., Sato Y., Imamura T., Shimada K., Kodama T., Kario K., Asada Y. Plasma Pentraxin 3, but not high-sensitivity C-reactive protein, is a useful inflammatory biomarker for predicting cognitive impairment in elderly hypertensive patients. J. Gerontol. A: Biol. Sci. Med. Sci. 2010, 65:547-552.
109. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res. 2000, 887:80-89.
110. Yilmaz M.I., Axelsson J., Sonmez A., Carrero J.J., Saglam M., Eyileten T., Caglar K., Kirkpantur A., Celik T., Oguz Y., Vural A., Yenicesu M., Lindholm B., Stenvinkel P. Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria. Clin. J. Am. Soc. Nephrol. 2009, 4:535-541.
111. Yin G.N., Lee H.W., Cho J.Y., Suk K. Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases. Brain Res. 2009, 1265:158-170.
112. Zhang L., Gao J., Li L., Li Z., Du Y., Gong Y. The neuronal pentraxin II gene (NPTX2) inhibit proliferation and invasion of pancreatic cancer cells in vitro. Mol. Biol. Rep. 2010, (published online Dec. 16). 10.1007/s11033-010-0632-y.
113. Zhang Y.W., Thompson R., Zhang H., Xu H. APP processing in Alzheimer's disease. Mol. Brain 2011, 4:3.
114. Zotova E., Nicoll J.A., Kalaria R., Holmes C., Boche D. Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimer Res. Ther. 2010, 2:1.